Clemastine Treatment in Individuals With Williams Syndrome

• Status: Recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study explores the neurobiological etiology of Williams syndrome and potential therapeutic targets for associated social, motor, and cognitive abnormalities. The main translational objective will be to test the effectiveness of Clemasntine on neurocognitive and other associated abnormalities in individuals with Williams syndrome.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sheba Medical Center
• Collaborator: Tel Aviv University
• Treatments: Clemastine

Criteria

Inclusion Criteria:

• Individuals with Williams syndrome, which has been confirmed by genetic testing.

• Ages 6-30.

• Normal values in safety variables (e.g. Normal ECG 120-129/80-84).

• No change in psychotropic medications and dosage during the last 4 weeks.

• During the study, no pharmacological change that may impact the study (e.g. ADHD

• medications).

Exclusion Criteria:

• Individuals with another genetic disorder besides Williams syndrome.

• Individuals with Williams syndrome, younger than 6 or older than 30 years old.

• Significant change in normal values in safety variables (e.g. high or low ECG).

• Change in medications and dosage during the last 4 weeks prior the beginning and

• during the study.

• Pregnancy.

• Using addictive substances such as alcohol.